Education
About Us
Working with TipRanks
Follow Us
Biolidics Ltd. (SG:8YY)
SGX:8YY
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$124.81M
Enterprise ValueS$128.76M
Total Cash (Recent Filing)S$300.00K
Total Debt (Recent Filing)S$2.52M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)16.43
Price to Sales (P/S)36.30
P/FCF Ratio-12.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue RecoveryA ~381% year-over-year revenue surge indicates strong market traction for Biolidics’ diagnostic products and distribution channels. Sustained top-line expansion can allow the company to leverage fixed costs, improve operating leverage and create runway to invest in scale and margin improvement.
Recurring Consumables ModelSelling test kits plus per-test consumables creates recurring, annuity-like revenue and customer stickiness. This structural revenue mix improves predictability and lifetime value, supporting margin durability and cash flow stability as installed base and repeat testing grow.
Improving Free Cash Flow TrendPositive free cash flow growth signals improving liquidity and operational efficiency, reducing near-term financing reliance. If continued alongside revenue scale-up, this trend can fund R&D, manufacturing and working capital, aiding a durable transition toward self‑funding operations.
Bears Say
Persistent UnprofitabilityOngoing negative net profit and EBIT margins, plus falling gross margin, mean revenue growth is not yet translating into earnings. Structural margin pressure constrains retained earnings, limits reinvestment capacity and necessitates sustained cost or pricing improvements to achieve durable profitability.
Negative Operating Cash FlowCore operations failing to generate positive operating cash raises refinancing and liquidity risks. Even with improving free cash flow, negative OCF constrains funding for sales expansion, manufacturing scale-up and R&D, threatening the longevity of growth unless cash conversion improves.
Moderate Leverage & Weak ROEA debt-to-equity above 1 combined with negative ROE signals elevated financial risk and capital inefficiency. Higher leverage increases interest and refinancing burdens, reducing flexibility to invest in growth or withstand downturns, and makes value creation harder for shareholders over the medium term.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$124.81M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.
Technical Analysis
HC Surgical Specialists Ltd
―
Hyphens Pharma International Ltd.
―
iX Biopharma Ltd.
―
VicPlas International Ltd.
―
Singapore Paincare Holdings Limited
―